AMAG Pharmaceuticals, Inc. to Host Conference Call on January 22, 2014 at 7:30 a.m. E.T. to Provide a Regulatory Update

AMAG, BIOGY

WALTHAM, Mass., Jan. 21, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will host a conference call to provide a regulatory update regarding the FDA's action on the company's supplemental new drug application for Feraheme® before the U.S. financial markets open on Wednesday, January 22, 2014, at 7:30 a.m. E.T.

To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 9:30 a.m. E.T. on January 22, 2014 through midnight on February 22, 2014. To access a replay of the conference call, dial (855) 859-2056 from the United States or (404) 537-3406 for international access. The pass code for the live call and the replay is 43512081.

The call will be webcast and accessible through the Investors section of the company's website at www.amagpharma.com. The webcast replay will be available from approximately 10:30 a.m. E.T. on January 22, 2014 through midnight February 22, 2014.

About AMAG

AMAG Pharmaceuticals, Inc. is a rapidly growing, specialty pharmaceutical company, supported by a talented and passionate workforce. AMAG currently markets Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse in the United States. Along with driving organic growth of its products, AMAG intends to expand its portfolio with additional commercial-stage specialty products. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers. The company's primary goal is to bring to market therapies that provide clear benefits and improve patients' lives. For additional company information, please visit www.amagpharma.com.

CONTACT: AMAG Pharmaceuticals, Inc.
         Amy Sullivan, 617-498-3303

AMAG Pharmaceuticals logo


Rate this press release
3 stars
v
Usefulness

Clarity

Credibility
Add to favourites icon Add to favourites

top
top